HEREDITAS, published by BMC, is a distinguished Open Access journal that has been a pivotal platform for the dissemination of cutting-edge research in the fields of genetics and biomedical sciences since its inception in 1920. With an impressive history spanning over a century, HEREDITAS has maintained a strong commitment to providing unrestricted access to high-quality scientific articles, ensuring that researchers and practitioners worldwide can share their findings and insights. This journal, which operates from its headquarters in the United Kingdom, is positioned within the Q3 quartile for Genetics and Q2 for miscellaneous Medicine categories according to the 2023 metrics, reflecting its significant yet evolving role in the academic landscape. Researchers are drawn to HEREDITAS not only for its legacy but also for its impact factor and contributions to the broader understanding of hereditary processes. The journal serves as an essential resource for students, scholars, and professionals who are keen on advancing the knowledge frontiers in genetics and related disciplines. With its open access policy implemented since 2005, HEREDITAS not only champions the principle of knowledge dissemination but also plays a crucial role in fostering collaborative research efforts across the globe.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

JOURNAL OF MEDICAL GENETICS, published by the BMJ PUBLISHING GROUP, stands as a premier platform in the field of genetics, focusing on both fundamental genetic research and its clinical applications. With a distinctive legacy dating back to 1965 and a significant role in advancing the understanding of genetic disorders, this journal has established itself in the top tiers with a commendable Q1 category ranking in both Genetics and Clinical Genetics as of 2023. The journal's impact is underscored by its Scopus rankings, placing it among the leading journals in the fields of medicine and genetics. Researchers and practitioners are drawn to its rigorous peer-review process and its commitment to disseminating high-quality research findings, critical reviews, and innovative clinical practices. While it is not an open-access journal, the insights provided are invaluable for anyone looking to deepen their knowledge or contribute to the burgeoning field of medical genetics.

Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.

The EUROPEAN JOURNAL OF HUMAN GENETICS, published by SpringerNature, stands as a preeminent platform in the field of genetics and clinical genetics. Established in 1993, this prestigious journal, with an ISSN of 1018-4813 and an E-ISSN of 1476-5438, has consistently maintained its position in the Q1 quartile for both Genetics and Clinical Genetics categories as of 2023, reflecting its significant contributions to the field. Its impact is further underscored by its impressive Scopus rankings, placing it in the 92nd percentile among clinical genetics journals. The journal aims to disseminate cutting-edge research, case studies, and reviews that advance our understanding of human genetics, promoting collaboration and innovation among researchers, professionals, and students alike. While it does not currently offer open access, the journal provides substantial value through its rigorous peer review process and commitment to quality. As it continues to shape the future of genetic research through 2024 and beyond, the EUROPEAN JOURNAL OF HUMAN GENETICS remains an essential resource for those dedicated to exploring the complexities of human heredity.

Human Genetics and Genomics Advances is a premier academic journal published by Elsevier, dedicated to the field of human genetics and genomic medicine. With an ISSN of 2666-2477, this journal has quickly established itself as a leading platform for disseminating cutting-edge research from its inception in 2020. Featured prominently in Q1 categories for both Clinical Genetics and Molecular Medicine as of 2023, it ranks favorably among its peers, reflected in its Scopus rankings. The journal not only offers valuable insights into the latest advancements and applications in genetics but also facilitates open dialogue among researchers, clinicians, and students. As an open access publication, it ensures that groundbreaking findings in genetics are readily accessible to a global audience, promoting knowledge sharing and collaboration. Human Genetics and Genomics Advances continues to be instrumental in moving the field forward, providing a vital resource for those at the forefront of genetic and genomic research.

Frontiers in Genetics is a premier academic journal dedicated to advancing the field of genetics through high-quality, peer-reviewed research. Published by FRONTIERS MEDIA SA in Switzerland since 2010, this Open Access journal provides a platform for researchers and practitioners to disseminate innovative findings across various subfields, including clinical genetics and molecular medicine. With a notable emphasis on interdisciplinary approaches, the journal holds a strong position in the academic landscape, achieving Q2 rankings in key categories such as Genetics and Molecular Medicine in 2023. Not only does Frontiers in Genetics contribute to the scholarly dialogue by publishing impactful studies, but it also promotes accessibility to vital research, ensuring that knowledge is available to a global audience. This journal is a vital resource for researchers, professionals, and students looking to stay at the forefront of genetic discoveries and their applications, reflective of its engagement with contemporary challenges in genetics and healthcare.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.

Cold Spring Harbor Perspectives in Medicine is a premier academic journal published by the esteemed COLD SPRING HARBOR LAB PRESS that has become a crucial resource in the fields of Biochemistry, Genetics, and Medicine. With an impressive impact factor and consistently ranked in the Q1 quartile for both biochemistry and general medicine—as evidenced by its Scopus rankings of #21 and #26 respectively—this journal serves as an essential platform for disseminating high-quality research and comprehensive reviews from leading experts. Covering a convergence of knowledge spanning from 2011 through 2024, it plays a vital role in advancing the understanding of medical science. Researchers, professionals, and students alike benefit from Cold Spring Harbor Perspectives in Medicine, which offers a depth of insight into critical topics, emerging trends, and essential developments within the medical community. Join the conversation and contribute to the ongoing dialogue that drives innovation and excellence in medical research.

GENES CHROMOSOMES & CANCER, published by Wiley, is a premier journal in the intertwined fields of cancer research and genetics. With an ISSN of 1045-2257 and an e-ISSN of 1098-2264, this journal has been a significant outlet for innovative research since its inception in 1989, continuing through to 2024. Positioned in the Q2 quartile of both Cancer Research and Genetics categories in 2023, it reflects a strong impact in the scientific community, as evidenced by its Scopus rankings—99th in Genetics and 83rd in Cancer Research. Though it does not provide open access options, GENES CHROMOSOMES & CANCER offers valuable insights that foster collaboration and discovery among researchers, professionals, and students dedicated to understanding the genetic underpinnings of cancer. With its reputable standing, this journal is a vital resource for those aspiring to contribute meaningful advancements in cancer genetics and therapeutic interventions.